Spectrometric Analysis of Process Variations in Remifentanil

Area of Science:

• Pharmaceutical Sciences
• Analytical Chemistry
• Drug Quality Control

Background:

• ULTIVA® (remifentanil hydrochloride) is a potent μ-opioid agonist used for intravenous anesthesia.
• Ensuring consistent drug quality and formulation is critical for patient safety and therapeutic efficacy.
• Fourier transform near-infrared spectrometry (FTNIR) is a valuable tool for analyzing drug composition and detecting variations.

Purpose of the Study:

• To assess intra-lot and inter-lot variability in ULTIVA® drug quality.
• To identify potential inconsistencies in formulation or materials used in ULTIVA® production.
• To evaluate the effectiveness of FTNIR in detecting subtle differences in drug spectra.

Main Methods:

• Drug Quality Study (DQS) was conducted to measure spectral variability.
• Fourier transform near-infrared spectrometry (FTNIR) was employed for spectral analysis.
• Statistical methods, including multidimensional standard deviations (SDs) and subcluster detection tests, were used to identify outliers.

Main Results:

• One vial from lot 220453F exhibited significant spectral deviation (122 SDs) from other vials of lot 30020BF.
• Analysis of a larger spectral library (90 vials, 9 lots) revealed outliers.
• 39% of library vials (35 out of 90) showed spectral differences, suggesting the presence of different materials compared to the main group.

Conclusions:

• FTNIR analysis detected significant variability in ULTIVA® drug quality across different lots and potentially within lots.
• The presence of outlier vials suggests possible inconsistencies in manufacturing or raw materials.
• Further investigation is warranted to identify the specific causes of spectral variations and ensure consistent drug quality.